Speaker
Summary
Targeted radionuclide therapy has been an important clinic breakthrough, particularly tar-geted α-therapy with α-particle-emitting isotopes such as 225Ac, 223Ra, 213Bi, 212Pb, has demonstrated a successful clinic trial effect. Significant efforts are being made worldwide to develop stable radiopharmaceuticals with α-emitting isotopes. However, the major bottleneck for conducting translational research and future extensive clinical treatments is the limited availability of those α-emitting isotopes. 225Ac isotope can be produced by the spallation reaction 232Th(p,x) 225Ac on thorium targets with proton energies ranging from 100 to 1,000 MeV at beam currents hundreds eμA (1-2). An α-particle-emitting medical -isotope production facility named as IP-SAFE based on a high-intensity proton superconducting linac is being built by IMP in Lanzhou.
IP-SAFE facility is dedicated to demonstration of high-yields production of 225Ac and 223Ra medical isotopes with proton beam energy 115 MeV and beam current 0.5-1.0 mA. IP-SAFE facility consists of a 115 MeV superconducting proton linac accelerator, two irradiation thorium-target stations, two lines of chemical-separation dedicated to high-purity 225Ac and 223Ra isotopes simultaneous-separation, radioactive waste collection and treatment system, and other auxiliary sub-systems. The unique feature of the IP-SAFE facility is high-intensity proton beam operation and multiple thorium-targets in order to achieve high yields production of the 225Ac and 223Ra isotopes. There are two irradiation target-stations, one for low intensity beam 250-300 eμA with single-target of three cassettes, the other one for high-intensity beam 500-1000 eμA with 16-targets of three cassettes by beam scanning irradiation. The presentation will focus on detailed technical design of the IP-SAFE facility and construction status.
The 115 MeV superconducting proton linac will start beam commissioning in March-April 2026. The target stations and isotope separation systems with the hot cells will be ready for beam tests in May 2026. It is expected to start 225Ac isotope production at low beam intensity in June-July 2026.
| Are you interested/eligible for the Young Session? | No, I am not eligible |
|---|
